Literature DB >> 24525201

Lenalidomide and second malignancies in myeloma patients.

Guy Pratt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24525201     DOI： 10.1016/S1470-2045(14)70001-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.

Authors:  Idrees Mian; Denái R Milton; Nina Shah; Yago Nieto; Uday R Popat; Partow Kebriaei; Simrit Parmar; Betul Oran; Jatin J Shah; Elisabet E Manasanch; Robert Z Orlowski; Elizabeth J Shpall; Richard E Champlin; Muzaffar H Qazilbash; Qaiser Bashir
Journal:  Cancer       Date:  2016-09-28       Impact factor: 6.860

2.  Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary Malignancies in Myeloma.

Authors:  Junichiro Takano; Shotaro Hagiwara; Akiyoshi Miwa
Journal:  Rare Tumors       Date:  2015-12-29

Review 3.  The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.

Authors:  Liesbeth Bieghs; Hans E Johnsen; Ken Maes; Eline Menu; Els Van Valckenborgh; Michael T Overgaard; Mette Nyegaard; Cheryl A Conover; Karin Vanderkerken; Elke De Bruyne
Journal:  Oncotarget       Date:  2016-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.